Today: 17 May 2026
Axon Stock: Q1 Revenue Jumps 34% as AI and Drone Demand Lift 2026 Outlook

Axon Stock: Q1 Revenue Jumps 34% as AI and Drone Demand Lift 2026 Outlook

SCOTTSDALE, Arizona, May 6, 2026, 14:01 MST

  • Axon bumped its 2026 revenue growth outlook to 30%–32%, an increase from the earlier 27%–30% range, after first-quarter revenue came in ahead of estimates.
  • Axon reported a 35% jump in software and services revenue to $355 million. Artificial intelligence product revenue? That surged by more than 700%.
  • The Taser and body-camera maker pointed to margin pressure, citing tariffs, the Dedrone product mix, and deployment costs.

Axon Enterprise posted a 34% surge in first-quarter revenue on Wednesday and boosted its full-year sales guidance, the company said, with demand for police software, Tasers, body cameras, counter-drone tech and AI products staying strong even as costs weighed.

Revenue at the Scottsdale, Arizona-based company climbed to $807 million, beating the $780.6 million Zacks consensus estimate cited just a day ago. Adjusted earnings landed at $1.61 per share—just missing the $1.66 Zacks forecast, but slipping past FactSet’s $1.60 figure, which appeared in market data feeds after results dropped.

Timing isn’t incidental here. Axon wants to convince investors it has growth left outside its main Taser business, even as shares have struggled this year. MarketScreener data puts the stock at $385.86 at the close on Nasdaq, up 1.38% for the day, but still roughly 32% lower for 2026.

Axon raised its 2026 revenue growth outlook to a range of 30% to 32%, up from the previous 27% to 30% forecast. The company is sticking with its adjusted EBITDA margin goal of 25.5%. Adjusted EBITDA removes interest, taxes, depreciation, amortization and certain other expenses from profit calculations.

Software and services kept their shine, with revenue climbing 35% to $355 million. Annual recurring revenue — basically the annualized total from steady software and service contracts — also jumped 35%, hitting $1.5 billion.

Axon reported a surge of over 700% year-over-year for its AI Era Plan lineup—Draft One and Axon Assistant both included. Chief Executive Rick Smith pointed to “greater transparency and higher expectations” among customers, adding that the company was “breaking down information barriers” through its secure platform. Axon IR

Axon’s connected devices segment—which covers Tasers, body cams, and various other pieces of hardware—jumped 33% to $453 million. Platform Solutions nearly doubled, up 95%, thanks in part to Dedrone, the company’s unit focused on counter-drone technology. These systems spot, track, or disrupt drones that aren’t authorized.

That move squarely lines up Axon with a broader set of public-safety tech rivals, beyond its usual hardware or weapons foes. In its securities filing, Axon specifically lists Motorola Solutions’ CommandCentral Aware as a competitor to Fusus, Axon’s real-time operations platform. Motorola, for its part, also markets public-safety software, video surveillance, and body-camera products to law enforcement and security agencies.

The catch: margins and cash took a hit. Axon’s gross margin dropped 150 basis points from last year, landing at 59.1%. The company cited global tariffs, increased Dedrone revenue, and rising professional services expenses. Operating cash flow swung to a $32 million outflow, compared with a $26 million inflow a year ago, with inventory spending and higher interest costs partly to blame.

It wasn’t a unanimous call going into earnings. On Tuesday, Bob Lang at TheStreet Pro noted traders seemed to be keeping their distance, describing the stock as moving in a narrow band and the chart as “not pricing in too much excitement.” TheStreet Pro

Axon’s growing backlog leaves some breathing space, though it also ups the ante on execution. The company’s future contracted bookings shot up 44% to $14.3 billion. Axon anticipates delivering on 20% to 25% of those commitments within the next year, leaving the bulk to be recognized over the next ten years.

The next question: can stronger sales actually deliver more consistent cash and ease the pressure on margins? Axon is sticking to its forecast, projecting operating cash flow above $600 million for the full year and free cash flow near $450 million—even with the cash drain seen in the first quarter.

Stock Market Today

  • Congresswoman's Frequent Nasdaq Stock Purchases Spark Conflict of Interest Concerns
    May 16, 2026, 8:10 PM EDT. Rep. April McClain Delaney (D-Md.) has disclosed multiple purchases of Nasdaq Inc. shares, totaling 11 acquisitions over two years, with eight trades in 2026 alone. Nasdaq, which operates a major U.S. stock exchange and has significant crypto trading interests, is at the center of scrutiny due to her role on the House Subcommittee on Commodity Markets and Digital Assets. This panel advanced the Digital Assets Market Clarity Act, pending Senate vote, which could directly benefit Nasdaq's crypto business. The repeated buys, especially amid pending legislation, raise potential conflict of interest and insider trading concerns. Market watchers and social media trackers highlight the timing and volume of the congresswoman's stock activity. Benzinga continues to monitor congressional trading for transparency and regulatory implications.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Snap Stock Slides After Q1 Revenue Jump As Perplexity Deal Ends And Guidance Stays Cautious
Previous Story

Snap Stock Slides After Q1 Revenue Jump As Perplexity Deal Ends And Guidance Stays Cautious

DoorDash Stock Jumps After Order Forecast Beats Wall Street, Even as Profit Slips
Next Story

DoorDash Stock Jumps After Order Forecast Beats Wall Street, Even as Profit Slips

Go toTop